SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced a podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja, with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on podcast platforms and can be viewed now on YouTube.
In the "Target: Cancer Podcast," Dr. Juneja interviews Dr. Kumar about 'The Vaccine That Could End Breast Cancer.' The doctors discuss the unique science behind Anixa's vaccine technology, which enables the immune system to destroy cancer cells at the earliest stage and prevent them from growing and spreading to surrounding tissues and structures. Commenting on the potential for Anixa's vaccines, Dr. Juneja stated, "It would be wonderful if we could do for cancer what we have done for infectious diseases."
"It was a pleasure to join Dr. Juneja on his internationally-accessed Target: Cancer Podcast channel," said Dr. Amit Kumar. "His forum for the fight against cancer illuminates the best ideas in cancer research that offer the best possibilities for patients and the medical community. I was proud to share our groundbreaking science for cancer vaccination and the value it holds."
Dr. Sanjay Juneja is a board-certified hematologist and medical oncologist currently practicing in Baton Rouge, Louisiana. Visit Dr. Juneja at sjunejamd.com and @theoncdoc on social media platforms.
About Target: Cancer Podcast
Target: Cancer is a channel where people can learn about all the newest technologies and treatments for cancer. Combining technology, doctors, and patients together in a way that is collaborative, informative, and enlightening.
The podcast was conceived and is produced by health data innovator, xCures. The host, Dr. Juneja and guests talk about the future of cancer treatment, addressing questions like, 'what does that future look like?', and 'why isn't it here now?' Everyone is terrified of cancer, but if the medical community is able to understand it better and know how to win the battle, it's going to give patients and doctors the assurance they desire.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10- Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward- looking statements when evaluating the information presented in this press release.
CONTACT:
Mike Catelani
President, COO & CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
408-708-9808
| Last Trade: | US$3.20 |
| Daily Change: | 0.14 4.58 |
| Daily Volume: | 639,563 |
| Market Cap: | US$102.980M |
November 18, 2024 October 31, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
